#ESMO26 Landmark Phase III PANKU-Lung01 presentation by Dr. Li Zhang (Sun Yat-sen University Cancer Center):
🧬 Drug: Izalontamab Brengitecan (iza-bren, BL-B01D1) — bispecific EGFR×HER3 Topo-I ADC
👥 Population: EGFRm NSCLC progressing on 3rd-gen EGFR TKI (N=432)
📊 Primary & Secondary Endpoints:
• mPFS (BICR): 11.1 mo vs 5.7 mo | HR 0.40 (95% CI 0.31-0.51), p<0.0001
• cORR: 60.2% vs 34.5% | mDoR: 10.4 mo vs 5.7 mo
• OS: Immature, 18-mo OS rate 68.8% vs 55.3%
• Safety: Hematologic AEs manageable with standard care; ILD rate 0.9%
Dr. Zhang's presentation highlights iza-bren as a transformative targeted strategy for post-TKI EGFRm NSCLC!
#LCAD #NSCLC #OncoX #ESMO26
12 views · 0 likes · 0 reposts · 0 replies
Phase II study of izalontamab brengitecan (Iza-bren) plus osimertinib in patients with EGFR mutant locally advanced or metastatic non-small cell lung cancer (NSCLC)
https://esmocongress.esmo.orgPANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.orgSource: Young Kwang Chae, MD, MPH, MBA · x.com